EUCTR2007-004088-22-IT进行中（未招募）不适用
Efficacy and safety of Fibrinogen Concentrate (Human) for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •?Male or female, any age. ?Documented congenital fibrinogen deficiency, expected to require treatment for bleeding: - Fibrinogen deficiency manifested as afibrinogenemia or severe hypofibrinogenemia (plasma fibrinogen level <50 mg/dL). - Plasma fibrinogen activity <50 mg/dL and fibrinogen antigen <1.2 times the plasma fibrinogen activity at screening or previously confirmed in Study BI3023_2001. If plasma fibrinogen activity at screening is undetectable, the fibrinogen antigen at screening must be <20 mg/dL. For those subjects who present to the clinic with an acute bleed without having had a screening visit and who are known to have either afibrinogenemia or severe hypofibrinogenemia (confirmation from medical record or verbal communication to be recorded in source documents), the plasma fibrinogen activity and antigen is to be determined at the CSL Behring laboratory with blood drawn on the day of enrolment (Day 1) and in a non-bleeding state on Day 45, as would have been done at screening. ?Presenting with an episode of acute bleeding (either spontaneous or after trauma) not requiring surgery. ?Provide a signed informed consent (from the subject or their legally authorized representative). A screening informed consent form is to be signed by all subjects who participate in the screening visit and a study informed consent is to be signed by all subjects on Day 1 prior to any study activities.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •?Life expectancy <6 months. ?Bleeding disorder other than congenital fibrinogen deficiency, but including dysfibrinogenemia. ?Treatment with: - Any IMP in the 30 days prior to enrollment (Day 1). - Any fibrinogen concentrate or other fibrinogen containing blood product in the 2 weeks prior to screening and the 2 weeks prior to enrollment (Day 1). - Any coagulation active drug (i.e. non-steroidal-antirheumatics, warfarin, cumarin derivates, platelet aggregation inhibitors) in the 2 weeks prior to screening, the 2 weeks prior to enrollment (Day 1), or as a planned or expected medication during the time period from Day 1 until 24 hours after the last FCH infusion. ?Presence or history of: - Hypersensitivity to FCH. - Deep vein thrombosis or pulmonary embolism within 1 year prior to enrollment. - Arterial thrombosis within 1 year prior to enrollment. - Hypersensitivity to human plasma proteins. ?History or presence of esophageal varicose bleeding. ?End stage liver disease (i.e. Child Pugh score B or C). ?Planned or expected surgery (i.e. for bleedings from aneurysm or splenic rupture). ?Pregnancy, or an intention to become pregnant during the study. ?Currently breast-feeding, or with the intention of breast-feeding during the study. ?Human immunodeficiency virus (HIV) positive. ?Polytrauma, present or within 6 months prior to enrollment. ?Suspicion of an anti fibrinogen inhibitor as indicated by previous IVR (there is no test on inhibitors), if available (<0.5 (mg/dL)/(mg/kg)). ?Previous inclusion and treatment in the prospective part of the study. ?Participation in any clinical study in the 30 days prior to enrollment.
研究者
相似试验
进行中（未招募）
不适用
Efficacy and safety of Fibrinogen Concentrate (Human) for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiencyFibrinogen Concentrate (Human) (FCH) - efficacy and safetyCongenital fibrinogen deficiency (afibrinogenemia, severe hypofibrinogenemia)MedDRA version: 12.0Level: LLTClassification code 10016075Term: Factor I deficiencyEUCTR2007-004088-22-DECSL Behring GmbH23
招募中
2 期
Efficacy and safety of early fibrinogen concentrate substitution therapy for severe trauma patients receiving massive transfusions: prospective single arm clinical trialsevere traumaJPRN-UMIN000010294Saitama Medical Center, Saitama Medical University30
已完成
不适用
Effect of prophylactic fibrinogen on post operative bleeding in coronary artery bypass graft surgeryHemorrhage.Hemorrhage, not elsewhere classifiedIRCT201011085140N1Tehran University of Medical Sciences60
已完成
不适用
Application of fibrinogen concentrate (Fibrinogen HT) to uncontrollable massive bleedingMassive bleeding during 1)Pregnancy and delivery 2)Cardiovascular surgery 3)Gastrointestinal (including hepato-biliary-pancreatic) surgeryJPRN-UMIN000022666Kagoshima University Hospital, Division of blood transfusion medicine and cell therapy26
进行中（未招募）
1 期
Effect of prophylactic fibrinogen concentrate in surgery of abnormal lateral curvature of the spine: A randomized pilot study (EFISS trial)MedDRA version: 20.0Level: PTClassification code 10039727Term: Scoliosis surgerySystem Organ Class: 10042613 - Surgical and medical proceduresScoliosisEUCTR2021-005493-25-CZFakultní nemocnice Brno32